Biostem Technologies Inc. (BSEM)
OTC PINK OTC PINK Primary 
BioStem Technologies: A New Growth Star In Health Care
BioStem Technologies has enjoyed exceptional growth in its first year as a public company, with revenues soaring and earnings turning positive. The company's flagship product, AmnioWrap2, has been a major driver of revenue growth, with a strong sales performance. Despite rapid share price growth, BioStem stock is considered fairly valued based on Price/Sales ratios and is rated a strong buy with a one-year price target of $15.50.
BioStem Technologies, Inc. (BSEM) Q2 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q2 2024 Results Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executive Officer Michael Fortunato - Chief Financial Officer Conference Call Participants Brad Sorensen - Zacks Small-Cap Research Howard Gostfrand - American Capital Ventures Operator Thank you for standing by. My name is Regina, and I will be your conference operator today.
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
POMPANO BEACH, FL, 2024 — BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, reports financial results for the second quarter ended June 30, 2024. The Company will host a webcast and conference call on Monday, August 12, 2024, at 4:30 pm EDT.
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., August 5, 2024, — BioStem Technologies, Inc.
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
POMPANO BEACH, FL, July 10, 2024 – BioStem Technologies Inc.
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
Study published in peer-reviewed journal finds BioStem's products offer overall better treatment efficiency, and greater efficiency in general wound closure POMPANO BEACH, Fla., June 26, 2024 — BioStem Technologies Inc.
BioStem Technologies to Sponsor MRO Better Half Dash
POMPANO BEACH, Fla., May 29, 2024 – BioStem Technologies Inc.
